Kathleen J Young

US Patent:

6664068, Dec 16, 2003

Filed:

Apr 4, 2002

Appl. No.:

10/116370

Inventors:

Robert Mark - Lawrenceville NJ
Kathleen H. Young - Newtown PA
Andrew T. Wood - Newtown PA

Assignee:

Wyeth - Madison NJ

International Classification:

G01N 3353

US Classification:

435 71, 530350, 53038822, 5303877, 4241301, 4241341

Abstract:

The present invention relates, at least in part, to polypeptides which include Bcl-xL binding domains, novel Bcl-xL binding domains of Pablo polypeptides, nucleic acid molecules encoding such polypeptides, and uses thereof. For example, such polypeptides and nucleic acid molecules are useful in modulating apoptosis, particularly in neural cells, as well as in the treatment or prevention of disorders that can benefit from modulation of cell death.

US Patent:

6673540, Jan 6, 2004

Filed:

Nov 17, 2000

Appl. No.:

09/714258

Inventors:

Kathleen H. Young - Newtown PA
Bradley A. Ozenberger - Yardley PA

Assignee:

American Cyanamid Company - Madison NJ

International Classification:

C12Q 168

US Classification:

435 6, 536 231, 536 241, 435 71, 435 72, 435 731, 435 29, 435440, 435243, 4353201

Abstract:

This invention relates to modified host cells which express heterologous fused proteins and methods of screening for test samples having peptide binding activity; wherein the modified host cell comprises: (a) a gene sequence encoding a heterologous fusion protein; the fusion protein comprising a first peptide of a peptide binding pair, or segment of the first peptide, which is joined to either a DNA binding domain or its corresponding transcriptional activation domain of a transcriptional activation protein; (b) a gene sequence encoding a heterologous fusion protein, the fusion protein comprising a second peptide of the peptide binding pair in (a), or a segment thereof, fused to either a DNA binding domain or its corresponding transcriptional activation domain, whichever one is not employed in (a); (c) a reporter gene operatively associated with the transcriptional activation protein, or a portion thereof; (d) optionally, a deletion or mutation in the chromosomal DNA of the host cell for the transcriptional activation protein if present in the selected host cell.

US Patent:

6770446, Aug 3, 2004

Filed:

Apr 24, 2000

Appl. No.:

09/556390

Inventors:

Kathleen H. Young - Newtown PA
Jian Cao - Monmouth Junction NJ

Assignee:

Wyeth - Madison NJ

International Classification:

G01N 3353

US Classification:

435 71, 82542, 825421

Abstract:

This invention relates to novel modified host cells which express heterologous fused proteins and methods of screening for test samples having peptide-binding activity; wherein the modified host cell comprises: (a) a gene sequence encoding a heterologous fusion protein; said fusion protein comprising a first peptide of a peptide binding pair, or segment of said first peptide, which is joined to either a DNA binding domain or its corresponding transcriptional activation domain of a transcriptional activation protein; (b) a gene sequence encoding a heterologous fusion protein, said fusion protein comprising a second peptide of the peptide binding pair in (a), or a segment thereof, fused to either a DNA binding domain or its corresponding transcriptional activation domain, whichever one is not employed in (a); (c) a luciferase gene operatively associated with the transcriptional activation protein, or a portion thereof; (d) optionally, a deletion or mutation in the chromosomal DNA of the host cell for the transcriptional activation protein if present in the selected host cell.

US Patent:

7049083, May 23, 2006

Filed:

Jan 17, 2002

Appl. No.:

10/051843

Inventors:

Kathleen H. Young - Newtown PA, US
Kenneth J. Rhodes - Neshanic Station NJ, US

Assignee:

Wyeth - Madison NJ

International Classification:

C12N 15/63
C12N 1/15
C12N 1/16
C12N 15/00
G01N 33/566

US Classification:

435 72, 4353201, 435325, 4351731, 4352523, 4352542

Abstract:

Methods and compositions for identifying compounds which disrupt the functional interaction of an intracellular receptor region of an α-subunit of a voltage-gated ion channel and an amino-terminal inactivation region of an ion channel protein are disclosed. Compounds that disrupt the functional or binding interaction of these two regions have significant modulatory effects on ion channel activity, and thus are likely to be useful for treating and/or preventing a wide variety of diseases and pathological conditions associated with ion channel dysfunction. Such conditions include, for example, neurological disorders, cardiac diseases, metabolic diseases, tumor-driven diseases, and autoimmune diseases.

US Patent:

7049094, May 23, 2006

Filed:

Jan 17, 2002

Appl. No.:

10/051841

Inventors:

Kathleen H. Young - Newtown PA, US
Kenneth J. Rhodes - Neshanic Station NJ, US

Assignee:

Wyeth - Madison NJ

International Classification:

C12N 15/00
C12N 15/12
C12N 15/63
C07K 14/00
C07H 21/04

US Classification:

435 691, 4353201, 435325, 4241921, 4241851, 536 235, 530350

Abstract:

Methods and compositions for identifying compounds which disrupt the functional interaction of an intracellular receptor region of an α-subunit of a voltage-gated ion channel and an amino-terminal inactivation region of an ion channel protein are disclosed. Compounds that disrupt the functional or binding interaction of these two regions have significant modulatory effects on ion channel activity, and thus are likely to be useful for treating and/or preventing a wide variety of diseases and pathological conditions associated with ion channel dysfunction. Such conditions include, for example, neurological disorders, cardiac diseases, metabolic diseases, tumor-driven diseases, and autoimmune diseases.

US Patent:

7262336, Aug 28, 2007

Filed:

Apr 24, 2001

Appl. No.:

10/258561

Inventors:

Kathleen Young - Newtown PA, US
David S. Howland - Yardley PA, US
Karen L. Marquis - Yardley PA, US
Mark Ian Cockett - Newtown PA, US

Assignee:

Wyeth - Madison NJ

International Classification:

G01N 33/00
A01K 67/027
C12N 15/00

US Classification:

800 14, 800 3, 800 21

Abstract:

A transgenic rat containing in its genome a nucleotide sequence encoding a Ga subunit protein, which Ga protein subunit is uncoupled from regulation by Regulators of G-Protein Signaling (RGS) proteins, which Gx subunit protein is eventually the dominant-negative G188S mutant of Gax9, which nucleotide sequence is operatively associated with a neuron-specific expression control sequence, wherein the transgenic rat expresses the GA subunit protein in neural cells resulting in extended D-protein coupled receptor signaling mediated by the Ga subunit protein.

US Patent:

20020137049, Sep 26, 2002

Filed:

May 15, 2001

Appl. No.:

09/858155

Inventors:

Robert Mark - Lawrenceville NJ, US
Kathleen Young - Newtown PA, US
Andrew Wood - Newtown PA, US

Assignee:

American Home Products Corporation

International Classification:

C12Q001/68
C07H021/04
C12N009/64
C12P021/02
C12N005/06

US Classification:

435/006000, 435/226000, 435/069100, 435/325000, 435/320100, 536/023200

Abstract:

The present invention relates, at least in part, to polypeptides which include Bcl-xL binding domains, novel Bcl-xL binding domains of Pablo polypeptides, nucleic acid molecules encoding such polypeptides, and uses thereof. For example, such polypeptides and nucleic acid molecules are useful in modulating apoptosis, particularly in neural cells, as well as in the treatment or prevention of disorders that can benefit from modulation of cell death.

US Patent:

20030166850, Sep 4, 2003

Filed:

Mar 27, 2002

Appl. No.:

10/108210

Inventors:

Philip Jones - Cranbury NJ, US
Kathleen Young - Newtown PA, US

Assignee:

Wyeth - Madison NJ

International Classification:

C07K001/00
C07K014/00
C07K017/00

US Classification:

530/350000

Abstract:

The present invention relates to novel protein binding interactions, comprising a regulator of G-protein signalling protein (RGS) and a non G-protein binding partner. More particularly, the invention relates to a novel interaction between RGS9 and evectin polypeptides, the use of such polypeptides, as well as the production of such polypeptides. The invention relates also to identifying compounds which may be agonists, antagonists and/or inhibitors of RGS9 and/or evectin polypeptides, and therefore potentially useful in therapy. In particular embodiments, the RGS9 and evectin polypeptides produced are used in methods for assaying the effects of test compounds on the activity of RGS9-evectin dimers, methods for assaying the effects of test compounds on the activity of RGS9-evectin dimers comprised in transgenic animals encoding RGS9 and evectin, methods for diagnosis and treatment of diseases related to the activity of RGS9-evectin dimers and methods for modulating G-protein activity.